foto

Prof. PhD Y. Pinto

Position
Full Professor
Main activities
Patient care, Research, Other
Specialisation
Cardiology
Focus of research

 My research aims at understanding why an overloaded heart ultimately fails. Our leading thought is that the transition towards failure is governed by regulatory mechanisms that cause an accumulation of maladaptive changes. Our current focus is on genetic mechanisms and mechanisms involving RNA regulatory molecuales like microRNAs, lncRNAs and RNA splicing as key regulators of the adapative and maladaptive changes in the overloaded heart.

Key publications
  • Pinto Yigal M., Elliott Perry M., Arbustini Eloisa, Adler Yehuda, Anastasakis Aris, Böhm Michael, Duboc Denis, Gimeno Juan, de Groote Pascal, Imazio Massimo, Heymans Stephane, Klingel Karin, Komajda Michel, Limongelli Giuseppe, Linhart Ales, Mogensen Jens, Moon James, Pieper Petronella G., Seferovic Petar M., Schueler Stephan, Zamorano Jose L., Caforio Alida L. P., Charron Philippe Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases European heart journal 2016;37 (23):1850-1858 [PubMed]
  • Creemers Esther E., Bawazeer Amira, Ugalde Alejandro P., van Deutekom Hanneke W. M., van der Made Ingeborg, de Groot Nina E., Adriaens Michiel E., Cook Stuart A., Bezzina Connie R., Hubner Norbert, van der Velden Jolanda, Elkon Ran, Agami Reuven, Pinto Yigal M. Genome-Wide Polyadenylation Maps Reveal Dynamic mRNA 3'-End Formation in the Failing Human Heart Circulation research 2016;118 (3):433-438 [PubMed]
  • Khan Mohsin A. F., Reckman Yolan J., Aufiero Simona, van den Hoogenhof Maarten M. G., van der Made Ingeborg, Beqqali Abdelaziz, Koolbergen Dave R., Rasmussen Torsten B., van der Velden Jolanda, Creemers Esther E., Pinto Yigal M. RBM20 Regulates Circular RNA Production From the Titin Gene Circulation research 2016;119 (9):996-1003 [PubMed]
  • Amin Ahmad S., Giudicessi John R., Tijsen Anke J., Spanjaart Anne M., Reckman Yolan J., Klemens Christine A., Tanck Michael W., Kapplinger Jamie D., Hofman Nynke, Sinner Moritz F., Müller Martina, Wijnen Wino J., Tan Hanno L., Bezzina Connie R., Creemers Esther E., Wilde Arthur A. M., Ackerman Michael J., Pinto Yigal M. Variants in the 3 untranslated region of the KCNQ1-encoded K(v)7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner European heart journal 2012;33 (6):714-723 [PubMed]
  • van Rijsingen Ingrid A. W., Arbustini Eloisa, Elliott Perry M., Mogensen Jens, Hermans-van Ast Johanna F., van der Kooi Anneke J., van Tintelen J. Peter, van den Berg Maarten P., Pilotto Andrea, Pasotti Michele, Jenkins Sharon, Rowland Camilla, Aslam Uzma, Wilde Arthur A. M., Perrot Andreas, Pankuweit Sabine, Zwinderman Aeilko H., Charron Philippe, Pinto Yigal M. Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers A European Cohort Study Journal of the American College of Cardiology 2012;59 (5):493-500 [PubMed]
All Publications
Curriculum Vitae

                                                           CURRICULUM VITAE
                                                                   Yigal M. Pinto
                                      Professor in Molecular Biology of Heart Failure
                             Heart Failure Research Center & Department of Cardiology
 

MARITAL STATUS:  Married 3 children, Aylon, Soesja and Elya

OFFICE ADDRESS:  Heart Failure Research Center
                                    Academic Medical Center
                                    University of Amsterdam
                                     Meibergdreef 15
                                     1105 AZ Amsterdam, The Netherlands
                                     TEL +31 (020) 5664688
                                     FAX +31 (020) 6976177
                                     E-MAIL y.pinto@amc.uva.nl
 

EDUCATION
1983–1984 University of Groningen (English)
1984–1989 Medicine, University of Groningen, The Netherlands
1989–1990 Research fellow, Department of Vascular Medicine
                     (Dr. V.J.    Dzau)  Harvard Medical School, Boston, USA
1990–1993 University Hospital Groningen, clinical rotations Groningen:   MDdegree  April 23 1993
1993–1995 PhD researcher, Department of Clinical Pharmacology,  University of  Groningen
22/02/1995 PhD thesis entitled “Chronically activated tissue renin-angiotensin systems impaired cardiac function”: University of Groningen, Faculty of Medicine
 

POSTGRADUATE TRAINING & APPOINTMENTS
1996–1997 Research associate in Molecular Medicine, Benjamin Franklin University Hospital and Max Delbruck Center for Molecular Medicine, Berlin, Germany.
2001–01/2008 Cardiologist, Department of Cardiology, University Hospital Maastricht, The Netherlands
 

FACULTY APPOINTMENTS
2005–01/2008 Professor of Cardiology, Department of Cardiology, University Hospital Maastricht
2008– Professor in Molecular Biology of Heart Failure, University of Amsterdam, Faculty of Medicine
 

BIBLIOGRAPHY
Research papers
1. Hirsch AT, Pinto YM, Schunkert H, Dzau VJ. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990;66:22D-32D (review)
2. Pinto YM, van Wijngaarden J, van Gilst WH, de Graeff PA, Wesseling H. The effects of short- and long-term treatment with an ACE-inhibitor in rats with myocardial infarction. Basic Res Cardiol 1991;86(suppl 2):165-72
3. van Wijngaarden J, Pinto YM, van Gilst WH, de Graeff PA de Langen CD, Wesseling H. Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril. Cardiovasc Res 1991;25:936-42
4. Pinto YM, de Smet BGJL, van Gilst WH, Scholtens E, Monnink S, de Graeff PA, Wesseling H. Selective and time-related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc Res 1993;27:1933-8
5. Schunkert H, Ingelfinger JR, Hirsch AT, Pinto Y, Remme WJ, Jacob H, Dzau VJ. Feedback regulation of angiotensin converting enzyme activity and mRNA Levels by angiotensin II. Circ Res 1993;72:312-8
6. Paul M, Pinto Y, Schunkert H, Ganten D, Böhm M. Activation of the renin-angiotensin system in heart failure and hypertrophy: studies in human hearts and transgenic rats. Eur Heart J 1994;15(suppl D):63-7 (review)
7. Pinto YM, Buikema H, van Gilst WH. Hyperactive tissue renin-angiotensin systems in cardiovascular dysfunction: experimental evidence and clinical hypotheses. Clin Exp Hypertens A 1995;17:441-68 (review)
8. Pinto YM, van Gilst WH, Kingma JH Schunkert H. Deletion-type allele of the angiotensin converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. J Am Coll Cardiol 1995;25:1622-6
9. Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H, van Gilst WH. The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J 1996;17: 787-94
10. Langheinrich M, Lee MA, Böhm M, Pinto YM, Ganten D, Paul M. The hypertensive Ren-2 transgenic rat TGR (mREN2)27 in hypertension research. Characteristics and functional aspects. Am J Hypertens 1996;9:506-12 (review)
11. Pinto YM, Buikema H, van Gilst WH, Lie KI. Activated tissue renin-angiotensin systems add to the progression of heart failure. Basic Res Cardiol 1996;91(suppl 2):85-90 (review)
12. Pinto YM, van Veldhuisen DJ, Tjon-Ka-Jie RT, Rooks G, Netzer T, Lie KI. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure. Eur J Clin Pharmacol 1996; 50:265-8
13. Buikema H, Pinto YM, van Geel PP, Rooks G, de Langen CDJ, de Graeff PA, van Gilst WH. Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol 1997;29: 684-91
14. Flesch M, Schiffer F, Zolk O, Pinto YM, Rosenkranz S, Hirth-Dietrich C, Arnold G, Paul M, Böhm M. Contractile systolic and diastolic dysfunction in renin-induced hypertensive cardiomyopathy. Hypertension 1997;30: 383-91
15. Flesch M, Schiffer F, Zolk O, Pinto Y, Stasch JP, Knorr A, Ettelbrück S, Böhm M. Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca2+-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy. J Hypertens 1997;15:1001-9
16. Oosterga M, Voors AA, de Kam PJ, Schunkert H, Pinto YM, Kingma JH, van Gilst WH. Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction. Circulation 1997;95:2607-9
17. Pinto YM, Buikema H, van Gilst WH, Scholtens E, van Geel PP, de Graeff PA, Wagner J, Paul M. Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats. J Mol Med 1997;75: 371-7
18. Roks A, Buikema H, Pinto YM, van Gilst WH. The renin-angiotensin system and vascular function. The role of angiotensin II, angiotensin-converting enzyme, and alternative conversion of angiotensin I. Heart Vessels 1997; 12(suppl):119-24 (review)
19. Roks AJM, Pinto YM, Paul M, Pries F, Stula M, Eschenhagen T, Orzechowski HD, Gschwend S, Wilschut J, van Gilst WH. Vectors based on Semliki Forest virus for rapid and efficient gene transfer into non-endothelial cardiovascular cells: comparison to adenovirus. Cardiovasc Res 1997;35:498-504
20. Bohm M, Ettelbrück S, Flesch M, van Gilst WH, Knorr A, Maack C, Pinto YM, Paul M, Teisman ACH, Zolk O. -adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy. Cardiovasc Res 1998;40:146-55
21. Bohnemeier H, Pinto YM, Horkay F, Tóth M, Juhász-Nagy A, Orzechowski HD, Paul M. Endothelin-converting enzyme-1 mRNA expression human cardiovascular disease. J Cardiovasc Pharmacol 1998;31(suppl 1):S52-4
22. Bohnemeier H, Pinto YM, Horkay F, Tóth M, Juhász-Nagy A, Orzechowski HD, Böhm M, Paul M. Endothelin converting-enzyme-1 mRNA expression in human cardiovascular disease. Clin Exp Hypertens 1998;20:417-37

23. Engler S, Paul M, Pinto YM. The TGR(mRen2)27 hypertensive transgenic rat model of hypertension. Regul Pept 1998;77:3-8 (review)
24. Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 1998;39:77-88 (review)
25. Pinto YM, Pinto SJ, Paul M, Merker HJ. The electron microscopic morphology of the common carotid artery in rats. Ann Anat 1998;180:223-35
26. Stula M, Pinto YM, Gschwend S, Teisman AC, van Gilst WH, Böhm M, Dietz R, Paul M. Interaction of the renin-angiotensin system and the endothelin system in cardiac hypertropy. J Cardiovasc Pharmacol 1998,31(suppl 1):S403-5
27. Teisman ACH, Pinto YM, Buikema H, Flesch M, Böhm M, Paul M, van Gilst WH. Dissociation of blood pressure reduction from end-organ damage in TGR(mRen2)27 transgenic hypertensive rats. J Hypertens 1998;16:1759-65
28. van Geel PP, Pinto YM, Buikema H, van Gilst WH. Is the A1166C polymorphism of the angiotensin II type I receptor involved in cardiovascular disease? Eur Heart J 1998;19(suppl G):G13-7 (review)
29. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, Boomsma F, Netzer T, Man in ’t Veld AJ, Pinto YM, Lie KI, Crijns HJGM. High- versus low-dose ACE inhibition in chronic heart failure: a double blind, placebo controlled study of imidapril. J Am Coll Cardiol 1998;32:1811-8
30. Voors AA, Pinto YM, Buikema H, Urata H, Oosterga M, Rooks G, Grandjean JG, Ganten D, van Gilst WH. Dual pathways for angiotensin II formation in human internal mammary arteries. Br J Pharmacol 1998;125:1028-32
31. Zolk O, Flesch M, Schnabel P, Teisman AC, Pinto YM, van Gilst WH, Paul M, Böhm M. Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and ß-adrenergic neuroeffector mechanisms in transgenic (mRen2)27 rats. Br J Pharmacol 1998;123:405-12
32. Pinto YM, van Geel PP, Alkfaji H, van Veldhuisen DJ, van Gilst WH. Dosing of ACE inhibitors in left ventricular dysfunction: does current clinical dosing provide optimal benefit? J Cardiovasc Pharmacol 1999;34(suppl 1):S13-7 (review)
33. Pinto YM, van Gelder IC, Heeringa M, Crijns HJGM. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet 1999;353:980
34. Pinto YM, van Gilst WH. The ACE gene polymorphism: the good, the bad and the ugly. Cardiovasc Res 1999;43: 23-4 (editorial)
35. Roks AJM, van Geel PP, Pinto YM, Buikema H, Henning RH, de Zeeuw D, van Gilst WH. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 1999;34:296-301
36. Oosterga M, Voors AA, Buikema H, Pinto YM, Haber HE, Ebels T, Morshuis WJ, Kingma JH, Crijns HJGM, van Gilst WH for the QUO VADIS investigators. Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. Cardiovasc Drugs Ther 2000;14:55-60
37. Pinto YM, Bader M, Pesquero JB, Tschöpe C, Scholtens E, van Gilst WH, Buikema H. Increased kallikrein expression protects against cardiac ischemia. FASEB J 2000;14:1861-3
38. Pinto YM. Pals G, Zijlstra JG, Tulleken JE. Ehlers-Danlos syndrome type IV. N Eng J Med 2000;343:366-8 (correspondence)
39. Pinto YM, Pinto-Sietsma SJ, Philipp T, Engler S, Kossamehl P, Hocher B, Marquardt H, Sethmann S, Lauster R, Merker HJ, Paul M. Reduction in left ventricular messenger RNA for transforming growth factor 1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 rat. Hypertension 2000;36:747-54
40. Rothermund L, Pinto YM, Hocher B, Vetter R, Leggewie S, Kobemehl P, Orzechowski HD, Kreutz R, Paul M. Cardiac endothelin system impairs left ventricular function in renin-dependent hypertension via decreased sarcoplasmatic Ca2+ uptake. Circulation 2000;102:1582-8
41. Teisman ACH, van Veldhuisen DJ, Boomsma F, de Kam PJ, Tjeerdsma G, Pinto YM, de Zeeuw D, van Gilst WH. Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones. Int J Cardiol 2000;73:7-12
42. van Geel PP, Pinto YM, Voors AA, Buikema H, Oosterga M, Crijns HJGM, van Gilst WH. Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 2000;35:717-21
43. de Boer RA, Henning RH, Suurmeijer AJH, Pinto YM, Olthof E, Kirkels JH, van Gilst WH, Crijns HJGM, van Veldhuisen DJ. Early expression of natriuretic peptides and SERCA in mild heart failure: association with severity of the disease. Int J Cardiol 2001;78:5-12
44. Hoffmann S, Krause T, van Geel PP, Willenbrock R, Pagel I, Pinto YM, Buikema H, van Gilst WH, Lindschau C, Paul M, Inagami T, Ganten D, Urata H. Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load induced cardiac hypertrophy J Mol Med 2001;79:601-8
45. Oosterga M, Voors AA, Pinto YM, Buikema H, Grandjean JG, Kingma JH, Crijns HJGM, van Gilst WH. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). Am J Cardiol 2001; 87:542-6

46. Rothermund L, Pinto YM, Vetter R, Herfort N, Kossmehl P, Neumayer HH, Paul M, Kreutz R. Effects of angiotensin II subtype 1 receptor blockade on cardiac fibrosis and sarcoplasmic reticulum Ca2+ handling in hypertensive transgenic rats overexpressing the Ren2 gene. J Hypertens 2001;19:1465-72
47. van Geel PP, Pinto YM, Zwinderman AH, Henning RH, van Boven AJ, Jukema JW, Bruschke AVG, Kastelein JJ, van Gilst WH, Baxter GF. Increased risk for ischaemic events is related to combined RAS polymorphisms. Heart 2001;85:458-62
48. Roks AJM, Henning RH, Buikema H, Pinto YM, Kraak MJJ, Tio RA, de Zeeuw D, Haisma HJ, Wilschut J, van Gilst WH. Recombinant Semliki Forest virus as a vector system for fast and selective in vivo gene delivery into balloon-injured rat aorta. Gene Ther.\ 2002;9:95-101
49. Wagenaar LJ, Buikema H, Pinto YM, Gilst WH. Improvement of endothelial dysfunction in experimental heart failure by chronic RAAS-blockade: ACE-inhibition or AT(1)-receptor blockade? J Renin Angiotensin Aldosterone Syst 2001;2(suppl 1):S64-9
50. de Boer RA, Henning RH, Tio RA, Pinto YM, Brouwer RMHJ, Ploeg RJ, Böhm M, van Gilst WH, van Veldhuisen DJ. Identification of a specific pattern of downregulation in expression of isoforms of vascular endothelial growth factor in dilated cardiomyopathy. Heart 2002;88:412-4
51. de Boer RA, van Geel PP, Pinto YM, Suurmeijer AJH, Crijns HJGM, van Gilst WH, van Veldhuisen DJ. Efficacy of angiotensin II type 1 receptor blockade on reperfusion-induced arrhythmias and mortality early after myocardial infarction is increased in transgenic rats with cardiac angiotensin II type 1 overexpression. J Cardiovasc Pharmacol 2002;39:610-9
52. Gschwend S, Pinto-Sietsma SJ, Buikema H, Pinto YM, van Gilst WH, Schulz A, de Zeeuw D, Kreutz R. Impaired coronary endothelial function in a rat model of spontaneous albuminuria. Kidney Int 2002;62:181-91
53. Hocher B, Godes M, Olivier J, Weil J, Eschenhagen T, Slowinski T, Neumayer HH, Bauer C, Paul M, Pinto YM. Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. J Hypertens 2002;20:745-51
54. Pokharel S, Rasoul S, Roks AJM, van Leeuwen REW, van Luyn MJA, Deelman LE, Smits J, Carretero O, van Gilst WH, Pinto YM. N-acetyl-ser-asp-lys-pro inhibits phosphorylation of Smad2 in cardiac fibroblasts. Hypertension 2002;40:155-61
55. Tjeerdsma G, de Boer RA, Boomsma F, van den Berg MP, Pinto YM, van Veldhuisen DJ. Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. Int J Cardiol 2002;86:143-9
56. Bonne G, Yaou RB, Béroud C, Boriani G, Brown S, de Visser M, Duboc D, Ellis J, Hausmanowa-Petrusewicz I, Lattanzi G, Merlini L, Morris G, Muntoni F, Opolski G, Pinto YM, Sangiuolo F, Toniolo D, Trembath R, van Berlo JH, van der Kooi AJ, Wehnert M. 108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. Neuromuscul Disord 2003;13:508-15 (workshop report)
57. de Boer RA, Pinto YM, Suurmeijer AJH, Pokharel S, Scholtens E, Humler M, Saavedra JM, Boomsma F, van Gilst WH, van Veldhuisen DJ. Increased expression of cardiac angiotensin II type 1 (AT1) receptors decreases myocardial microvessel density after experimental myocardial infarction. Cardiovasc Res 2003;57:434-42
58. de Boer RA, Pinto YM, van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 2003;10:113-26 (review)
59. Gschwend S, Buikema H, Henning RH, Pinto YM, de Zeeuw D, van Gilst WH. Endothelial dysfunction and infarct-size relate to impaired EDHF response in rat experimental chronic heart failure. Eur J Heart Fail 2003;5:147-54
60. Gschwend S, Henning RH, Pinto YM, de Zeeuw D, van Gilst WH, Buikema H. Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade. Br J Pharmacol 2003;139:1317-25
61. Pokharel S, Sharma UC, Pinto YM. Left ventricular hypertrophy: virtuous intentions, malign consequences. Int J Biochem Cell Biol. 2003;35:802-6 (review)
62. van Berlo JH, Pinto YM. Polymorphisms in the RAS and cardiac function. Int J Biochem Cell Biol 2003;35:932-43
63. Diris JHC, Hackeng CM, Kooman JP, Pinto YM, Hermens WT, van Dieijen-Visser MP. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation 2004;109:23-5
64. de Boer RA, Pokharel S, Flesch M, van Kampen DA, Suurmeijer AJH, Boomsma F, van Gilst WH, van Veldhuisen DJ, Pinto YM. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med 2004;82:678-87
65. Folkeringa RJ, Pinto YM, Crijns HJGM. Aldosterone levels after angiotensin receptor blocker treatment. Circulation 2004;109:e182 (letter)
66. van Kimmenade RRJ, Bakker JA, van Dieijen-Visser MP, Pinto YM. (NT-pro)BNP: een nieuwe diagnostische bepaling bij de patiënt met hartfalen. Hart Bulletin 2004;35:114-117 (review)
67. van Kimmenade RRJ, Bakker JA, Crijns HJGM, van Dieijen-Visser MP, Pinto YM. The value of (NT-pro) BNP in the diagnosis, prognosis and treatment of congestive heart failure. Neth Heart J 2004;12:61-63

68. Pinto YM, de Windt L, van Gilst WH. Heart failure: chapter 1. Pathophysiology and molecular aspects of heart failure. Neth Heart J 2004;12:179-181 (self assessment)
69. Pokharel S, van Geel PP, Sharma UC, Cleutjens JPM, Bohnemeier H, Tian XL, Schunkert H, Crijns HJGM, Paul M, Pinto YM. Increased myocardial collagen content in transgenic rats overexpressing cardiac antgotensin-converting enzyme is related to enhanced breakdown of N-acetyl-ser-asp-pro and increased phosphorylation of Smad2/3. Circulation 2004;110:3129-35
70. Schellings MWH, Pinto YM, Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res 2004 64:24-31 (review)
71. Schroen B, Heymans S, Sharma U, Blankesteijn WM, Pokharel S, Cleutjens JPM, Porter JG, Evelo CTA, Duisters R, van Leeuwen REW, Janssen BJA, Debets JJM, Smits JFM, Daemen MJAP, Crijns HJGM, Bornstein P, Pinto YM. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res 2004;95:515-22
72. Sharma UC, Barenbrug P, Pokharel S, Dassen WRM, Pinto YM, Maessen JG. Systematic review of the outcome of aortic valve replacement in patients with aortic stenosis. Ann Thorac Surg 2004;78:90-5
73. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B, André S, Crijns HJGM, Gabius HJ, Maessen J, Pinto YM. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-8
74. Tian XL, Pinto YM, Costerousse O, Franz WM, Lippoldt A, Hoffmann S, Unger T, Paul M. Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats. Hum Mol Genet 2004;13: 1441-50
75. van Berlo JH, Duboc D, Pinto YM. Often seen but rarely recognised: cardiac complications of lamin A/C mutations. Eur Heart J 2004;25:812-4 (editorial)
76. Bekkers SCAM, Habets JHM, Cheriex EC, Palmans A, Pinto Y, Hofstra L, Crijns HJGM. Abdominal aortic aneurysm screening during transthoracic echocardiography in an unselected population. J Am Soc Echocardiogr 2005;18:389-93.
77. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, van de Werf F, Pinto YM, Janssens S. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005;112:1136-44
78. Sharma UC, Hofstra L, Pinto YM, Maessen JG. Real-time in vivo imaging of apoptotic cell membrane changes in monocytes and macrophages. Apoptosis 2005;5:1187-89
79. van Berlo JH, Voncken JW, Kubben N, Broers JLV, Duisters R, van Leeuwen REW, Crijns HJGM, Ramaekers FCS, Hutchison CJ, Pinto YM. A-type lamins are essential for TGF-1 induced PP2A to dephosphorylate transcription factors. Hum Mol Genet 2005;14:2839-49
80. van Berlo JH, de Voogt WG, van der Kooi AJ, van Tintelen JP, Bonne G, Yaou RB, Duboc D, Rossenbacker T, Heidbüchel H, de Visser M, Crijns HJGM, Pinto YM. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? J Mol Med 2005;83:79-83.
81. Eurlings LW, Januzzi JL, Pinto YM. Is acute heart failure a highly prevalent orphan disease? Eur Heart J 2006;27: 2619-20 (editorial)
82. Germans T, Wilde AAM, Dijkmans PA, Chai W, Kamp O, Pinto YM, van Rossum AC. Structural abnormalities of the inferoseptal left ventricular wall detected by carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol 2006;48:2518-23
83. Hermans JF, Christiaans I, van Tintelen JP, Wilde AAM, Pinto YM. GENCOR: a national registry for patients and families suffering from a familial heart disease in the Nettherlands. Net Heart J 2006;14:272-276
84. Heymans S, Pauschinger M, De Palma A, Kallwellis-Opara A, Rutschow S, Swinnen M, Vanhoutte D, Gao F, Torpai R, Baker AH, Padalko E, Neyts J, Schultheiss HP, Van de Werf F, Carmeliet P, Pinto YM. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 2006; 114:565-73
85. Januzzi JJ, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards AM. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled Analysis of 1256 Patients. The International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-7
86. Meune C, van Berlo JH, Anselme F, Bonne G, Pinto YM, Duboc D. Primary prevention of sudden death in patients with lamin A/C gene mutations. New Engl J Med 2006;354:209-10 (correspondence)
87. Schellings MWM, Baumann M, van Leeuwen REW, Duisters RFJJ, Janssen SHP, Schroen B, Peutz-Kootstra CJ, Heymans S, Pinto YM. Imatinib attenuates end organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 2006;47: 467-74
88. van Haaften RIM, Schroen B, Janssen BJA, van Erk A, Debets JJM, Smeets HJM, Smits JFm, van den Wijngaard A, Pinto YM, Evelo CTA. Biologically relevant effects of mRNA amplification on gene expression profiles. BMC Bioinformatics 2006;7:200
89. Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 2006;69:604-13 (review)
90. van Kimmenade RR, Januzzi JL, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, Mac Rae CA, Menheere PP, Pinto YM. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-24
91. van Kimmenade RRJ, Januzzi JL Jr, Baggish AL, Lainchbury JG, Bayes-Genis A, Richards AM, Pinto YM. Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardio-renal Interaction ? J Am Coll Cardiol 2006;48:1621-7
92. van Kimmenade R, van Dielen F, Bakker J, Nijhuis J, Crijns H, Buurman W, van Dieijen-Visser M, Greve JW, Pinto Y. Is brain natriuretic peptide production decreased in obese subjects? J Am Coll Cardiol 2006;47:886-7
93. van Kimmenade RRJ, Pinto YM, Bayes-Genis A, Lainchbury JG, Richards AM, Januzzi JL Jr. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol 2006;98:386-90
94. Baggish AL, van Kimmenade R, Bayes-Genis A, Davis M, Lainchbury JG, Frampton C, Pinto Y, Richards MA, Januzzi JL. Hemoglobin and N-terminal pro-brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure, Results from the International Collaborative of NT-proBNP (ICON) Study. Clin Chim Acta 2007;381:145-50
95. Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RRJ, Lainchbury JG, Richards AM, Ordoñez-Llanos J, Santaló M, Pinto YM, Januzzi JL Jr. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 2007;167:400-407
96. de Borst MH, Diks SH, Bolbrinker J, Schellings MW, van Dalen MBA, Peppelenbosch MP, Kreutz R, Pinto YM, Navis G, van Goor H. Profiling of the renal kinome: a novel tool to identify protein kinases involved in angiotensin II-dependent hypertensive renal damage. Am J Physiol Renal Physiol 2007;293:F428-37
97. Fisch S, Gray S, Heymans S, Haldar SM, Wang B, Pfister O, Cui L, Kumar A, Lin Z, Sen-Banerjee S, Das H, Petersen CA, Mende U, Burleigh BA, Zhu Y, Pinto YM, Liao R, Jain MK. Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy. Proc Natl Acad Sci 2007;104:7074-9
98. Germans T, Wilde AAM, van Echteld CJA, Kamp O, Pinto YM, van Rossum AC. Structural abnormalities of the left ventricle in hypertrophic cardiomyopathy mutation carriers detectable before the development of hypertrophy. Neth Heart J 2007;15:161-163
99. Schellings MW, Löwenberg B, Pinto YM. Another look at imatinib mesylate. N Engl J Med 2007;356:1183 (correspondence)
100. Schroen B, Leenders JJ, van Erk A, Bertrand AT, van Loon M, van Leeuwen RE, Kubben N, Duisters RF, Schellings MW, Janssen BJ, Debets JJ, Schwake M, Hoydal MA, Heymans S, Saftig P, Pinto YM. Lysosomal integral membrane protein-2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy. J Exp Med 2007;204:1227-35
101. Vanhoutte D, Schellings MWM, Götte M, Swinnen M, Herias V, Wild MK, Vestweber D, Chorianopoulos E, Cortés V, Rigotti A, Stepp MA, Van de Werf F, Carmeliet P, Pinto YM, Heymans S. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation 2007;115:475-82
102. van Kimmenade RRJ, Pinto Y, Januzzi JL Jr. When renal and cardiac insufficiencies intersect: is there a role for natriuretic peptide testing in the 'cardio-renal syndrome'? Eur Heart J 2007;24:2960-1 (editorial)
103. van Tintelen JP, Tio RA, Kerstjens-Frederikse WS, van Berlo JH, Boven LG, Suurmeijer AJH, White SJ, den Dunnen JT, te Meerman GJ, Vos YJ, van der Hout AH, Osinga J, van den Berg MP, van Veldhuisen DJ, Buys CHCM, Hofstra RMW, Pinto YM. Severe myocardial fibrosis caused by a deletion of the 5' end of the lamin A/C gene. J Am Coll Cardiol 2007;49:2430-9
104. Beautiful Study Group: Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. Cardiology 2008;110:271-82
105. Da Costa Martins PA, Bourajjaj M, Gladka M, Kortland M, van oort RJ, Pinto YM, Molkentin JD, de Windt LJ. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008;118:1567-1576
106. DeFilippi C, van Kimmenade RRJ, Pinto YM. Amino-terminal pro-B-type natriuretic peptide testing in renal disease. Am J Cardiol 2008;101(suppl):82A-8A
107. Eurlings LWM, Pinto YM, Dennert RM, Bekkers SCAM. Reversible isolated left ventricular non-compaction? Int J Cardiol 2008; in press
108. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, on behalf of the Beautiful investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-821
109. Hermans MCE, Faber CG, Pinto YM. Sudden death in myotonic dystrophy. N Engl J Med 2008;359:1626-1628 (correspondence)
110. Michielsen ECHJ, Bakker JA, van Kimmenade RRJ, Pinto YM, Van Dieijen-Visser MP. The diagnostic value of serum and urinary NT-proBNP for heart failure. Ann Clin Biochem 2008;45:389-94
111. Petretto E, Sarwar R, Grieve I, Lu H, Kumaran MK, Muckett PJ, Mangion J, Schroen B, Benson M, Punjabi PP, Prasad SK, Pennell DJ, Kiesewetter C, Tsheva ES, Corpuz LM, Webb MD, Conrad GW, Kurtz TW, Kren V, Fischer J, Hubner N, Pinto YM, Pravenec M, Aitman TJ, Cook SA. Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nat Genet 2008;40:546-52
112. van Kimmenade RRJ, Pinto YM, Januzzi JL Jr. Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations. Am J Cardiol 2008;101(suppl):39A-42A
113.

MISCELLANEOUS PUBLICATIONS
1. Wilde AAM, Pinto YM. The ECG or a (cardio)myopathy? Neth Heart J 2005;13:373 (rhythm puzzle)
2. Pinto Y. Op zoek naar de heilige graal. Continuum 2006;5:

BOOK CHAPTERS
1. van Geel PP, Pinto YM, Zwinderman AH. Genetic factors in the progression of atherosclerosis and response to cholesterol lowering drugs. In: Reiber JHC, van der Wall EE (eds). Dordrecht: Kluwer Academic Publishers 1998: 95-100
2. Pinto YM, de Windt L, van Gilst WH. Pathofysiologie en moleculaire aspecten van hartfalen. In: van Veldhuisen DJ, Voors AA (red). Leerboek hartfalen. Leusden: Mediselect BV 2003:11-23
3. Smits JFM, Struijker Boudier HAJ, van Zwieten PA, Danser AHJ, Pinto YM. Hart en vaten. In: Sitsen JMA, Smits JFM, Smits P, Cohen AF, Van Bortel LM (red). Farmacologie, derde druk. Maarssen: Elsevier gezondheidszorg 2004:281-353




 

Current research funding
  • AMC
  • AMC (Vrijgesteld)
  • Amgen BV
  • BAYER B.V.
  • MyoKardia, Inc. c/o Clintrax Global
  • Nederlandse Hartstichting
  • Netherlands Heart Institute
  • PPD Global Ltd
  • Stichting AMC Foundation (Vrijgesteld)
  • TFS Develop B.V.
  • UMC Utrecht
  • Vascular Research Network BV